高剂量伏美替尼在耐药性EGFR突变型NSCLC中的应用进展

doi:10.3760/cma.j.cn371439-20250929-00079

摘要/Abstract

摘要：

伏美替尼是我国自主研发的第三代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂，在EGFR突变型非小细胞肺癌（NSCLC）的治疗中展现出卓越疗效，尤其对T790M耐药突变及中枢神经系统转移患者具有显著优势。近年来，高剂量伏美替尼（160~240 mg/d）在难治性耐药NSCLC（包括P-环α-C螺旋压缩突变、软脑膜转移等）中的研究取得突破性进展。系统阐述高剂量伏美替尼在耐药性EGFR突变型NSCLC中的应用进展，可为优化难治性NSCLC的治疗策略提供循证依据。

关键词: 癌, 非小细胞肺, 抗药性, 肿瘤, 基因, erbB-1, 高剂量, 伏美替尼

Abstract:

Furmonertinib， a third-generation epidermal growth factor receptor （EGFR） tyrosine kinase inhibitor independently developed in China， has demonstrated remarkable efficacy in the treatment of EGFR-mutant non-small cell lung cancer （NSCLC）， particularly offering significant advantages for patients with T790M resistance mutations and central nervous system metastases. High-dose furmonertinib （160-240 mg/d） has been used for NSCLC with resistance-related EGFR mutations such as P-cyclin-dependent kinase α-C helix compression mutations and soft meningeal metastases. Systematically elaborating on the application progress of high-dose furmonertinib in drug-resistant NSCLC can provide evidence-based support for optimizing the treatment strategies for refractory NSCLC.

Key words: Carcinoma, non-small-cell lung, Drug resistance, neoplasm, Genes, erbB-1, High dose, Furmonertinib

曾娇, 丁江华. 高剂量伏美替尼在耐药性EGFR突变型NSCLC中的应用进展[J]. 国际肿瘤学杂志, 2026, 53(8): 491-495.

Zeng Jiao, Ding Jianghua. Application progress of high-dose furmonertinib in NSCLC with drug-resistant EGFR mutation[J]. Journal of International Oncology, 2026, 53(8): 491-495.

参考文献 43

[1]	罗毅君, 姚伟荣, 王晓莉. EGFR突变非小细胞肺癌脑转移靶向治疗进展[J]. 国际肿瘤学杂志, 2024, 51(11): 717-722. DOI:10.3760/cma.j.cn371439-20240318-00121.
[2]	Zhou Q, Zhao HY, Lu S, et al. Consensus on the lung cancer management after third-generation EGFR-TKI resistance[J]. Lacet Reg Health West Pac, 2024, 53: 101260. DOI: 10.1016/j.lanwpc.2024.101260.
[3]	Wang J, Qiu TY, Ren SX. Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines[J]. Cancer Biol Med, 2025, 22(2): 77-82. DOI: 10.20892/j.issn.2095-3941.2024.0497.
[4]	Wu SG, Qiu ZG, Shi HQ, et al. High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy[J]. BMC Cancer, 2025, 25(1): 926. DOI: 10.1186/s12885-025-14337-z. pmid: 40410780
[5]	Wang LY, Yang P, Luo H. Benefit of switching to firmonertinib following almonertinib-induced interstitial pneumonitis in a patient with advanced non-small-cell lung cancer: a case report[J]. Anticancer Drugs, 2025, 36(8): 682-685. DOI: 10.1097/CAD.0000000000001742. pmid: 40460030
[6]	Shi YK, Hu XS, Zhang SC, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study[J]. Lancet Respir Med, 2021, 9(8): 829-839. DOI: 10.1016/S2213-2600(20)30455-0.
[7]	Wu YL, Xue YR, Guo ZT, et al. Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes[J]. Acta Pharmacol Sin, 2022, 43(3): 747-756. DOI: 10.1038/s41401-021-00692-7.
[8]	Shi YK, Zhang SC, Hu XS, et al. Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation[J]. J Thorac Oncol, 2020, 15(6): 1015-1026. DOI: 10.1016/j.jtho.2020.01.010. pmid: 32007598
[9]	Hu M, Zhong CY, Wang JB, et al. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations[J]. Front Immunol, 2024, 15: 1399975. DOI: 10.3389/fimmu.2024.1399975.
[10]	Gawli CS, Patil CR, Patel HM. A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer[J]. Bioorg Med Chem, 2025, 123:118146. DOI: 10.1016/j.bmc.2025.118146.
[11]	Sun K, Wang P. A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review[J]. Front Oncol, 2024, 14: 1467722. DOI: 10.3389/fonc.2024.1467722.
[12]	Hu XS, Zhang SC, Ma ZY, et al. Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies[J]. BMC Med, 2023, 21(1): 164. DOI: 10.1186/s12916-023-02865-z.
[13]	Yang S, Liu Y, Zhao JZ, et al. EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of furmonertinib: a real-world study[J]. BMC Cancer, 2025, 25(1): 900. DOI: 10.1186/s12885-025-14313-7. pmid: 40394562
[14]	Tamura K, Yoshida T, Masuda K, et al. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases[J]. ESMO Open, 2023, 8(4): 101594. DOI: 10.1016/j.esmoop.2023.101594.
[15]	Li X, Zhao J, Wang Y, et al. Efficacy and safety of firmonertinib 160 mg combined with intrathecal injection pemetrexed in NSCLC patients with EGFR mutations and leptomeningeal metastases[J]. J Thorac Oncol, 20(3):S44-S45. DOI: 10.1016/S1556-0864(25)00249-7.
[16]	Zhao Q, Chen HY, Wang LL, et al. High-dose furmonertinib combined with bevacizumab and pemetrexed in non-small cell lung cancer patients with EGFR mutations and leptomeningeal metastasis: a prospective real-world study[J]. J Clin Oncol, 2025, 43(16_suppl): 8609. DOI: 10.1200/JCO.2025.43.16_suppl.8609.
[17]	Robichaux JP, Le XN, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC[J]. Nature, 2021, 597(7878): 732-737. DOI: 10.1038/s41586-021-03 898-1.
[18]	王俊, 冉凤鸣, 钱羽. 甲磺酸伏美替尼治疗非小细胞肺癌的研究进展[J]. 肿瘤学杂志, 2024, 30(9): 715-721. DOI: 10.11735/j.issn.1671-170X.2024.09.B001.
[19]	Ho HL, Wang FY, Chiang CL, et al. Dynamic assessment of tissue and plasma EGFR-activating and T790M mutations with droplet digital PCR assays for monitoring response and resistance in non-small cell lung cancers treated with EGFR-TKIs[J]. Int J Mol Sci, 2022, 23(19): 11353. DOI: 10.3390/ijms231911353.
[20]	He JY, Huang ZR, Han LZ, et al. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)[J]. Int J Oncol, 2021, 59(5): 90. DOI: 10.3892/ijo.2021.5270.
[21]	Sa HL, Shi Y, Ding CX, et al. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations[J]. J Cancer Res Clin Oncol, 2023, 149(10): 7729-7742. DOI: 10.1007/s00432-023-04726-x. pmid: 37004599
[22]	Borgeaud M, Parikh K, Banna GL, et al. Unveiling the landscape of uncommon EGFR mutations in NSCLC—a systematic review[J]. J Thorac Oncol, 2024, 19(7): 973-983. DOI: 10.1016/j.jtho.2024.03.016. pmid: 38499147
[23]	Xie YW, Fang HH, Cheng WW, et al. Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: a retrospective cohort study[J]. Int J Cancer, 2025, 157(5): 954-963. DOI: 10.1002/ijc.35460.
[24]	Le X, Yu Y, Zhao Y, et al. P3.12.38 updated clinical results from FURTHER: a study of firmonertinib in TKI-naive, advanced NSCLC with EGFR PACC mutations[J]. J Thorac Oncol, 2025, 20(10): S482. DOI: 10.1016/j.jtho.2025.09.900.
[25]	中国临床肿瘤学会非小细胞肺癌专家委员会, PACC专家共识编写小组. EGFR PACC突变晚期非小细胞肺癌诊疗专家共识(2025版)[J]. 中华肿瘤杂志, 2025, 47(9): 811-829. DOI: 10.3760/cma.j.cn112152-20250529-00247.
[26]	Qi RB, Fu XY, Yu YY, et al. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: a real-world study[J]. Lung Cancer, 2023, 184: 107346. DOI: 10.1016/j.lungcan.2023.107346.
[27]	斯晓燕, 王汉萍, 张晓彤, 等. 伏美替尼治疗奥希替尼耐药非小细胞肺癌16例[J]. 中国新药杂志, 2024, 33(7): 678-681. DOI: 10.3969/j.issn.1003-3734.2024.07.008.
[28]	中国临床肿瘤学会(CSCO), 非小细胞肺癌专家委员会, 抗肿瘤药物安全管理专家委员会. 三代EGFR-TKI在EGFR突变NSCLC治疗中应用的专家共识(2022年版)[J]. 中国肺癌杂志, 2022, 25(9): 627-641. DOI: 10.3779/j.issn.1009-3419.2022.101.47.
[29]	ClinicalTrials. gov. Furmonertinib in patients with leptomeningeal metastases associated with EGFR mutated NSCLC[EB/OL]. (2023-04-14)[2025-12-17]. https://clinicaltrials.gov/study/NCT05813522?intr=NCT05813522&rank=1.
[30]	ClinicalTrials. gov. A study of furmonertinib combined with chemotherapy in the treatment of NSCLC with leptomeningeal metastasis[EB/OL]. (2024-04-01)[2025-12-19]. https://clinicaltrials.gov/study/NCT06339242?intr=NCT06339242&rank=1.
[31]	ClinicalTrials. gov. Furmonertinib in EGFR-mutant NSCLC with brain metastases (iFORCE)[EB/OL]. (2025-12-19)[2025-12-23]. https://clinicaltrials.gov/study/NCT05465343?intr=NCT05465343&rank=1.
[32]	ClinicalTrials. gov. The efficacy of double-dose furmonertinib in the treatment of patients with slow osimertinib-resistant NSCLC[EB/OL]. (2023-11-07)[2025-12-22]. https://clinicaltrials.gov/study/NCT06117644?intr=NCT06117644&rank=1.
[33]	ClinicalTrials. gov. High-dose furmonertinib in the treatment in patients with advanced, metastatic NSCLC with progressed after first- or second-line treatment with osimertinib[EB/OL]. (2024-07-26)[2025-12-21]. https://clinicaltrials.gov/study/NCT06394674?intr=NCT06394674&rank=1.
[34]	Mountzios G, Saw SPL, Hendriks L, et al. Antibody-drug conjugates in NSCLC with actionable genomic alterations: optimizing smart delivery of chemotherapy to the target[J]. Cancer Treat Rev, 2025, 134: 102902. DOI: 10.1016/j.ctrv.2025.102902.
[35]	Mer AH, Mirzaei Y, Misamogooe F, et al. Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies[J]. Drug Deliv Transl Res, 2024, 14(11): 2963-2988. DOI: 10.1007/s13346-024-01564-3.
[36]	Oh SY, Lee YW, Lee EJ, et al. Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC[J]. Clin Cancer Res, 2023, 29(1): 221-232. DOI: 10.1158/1078-0432.CCR-22-2180.
[37]	Liu YT, Zhang YC, Zeng L, et al. RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET overexpression: results from a phase Ⅰb/Ⅱ trial[J]. J Clin Oncol, 2025, 43(16_suppl): 8592. DOI: 10.1200/JCO.2025.43.16_suppl.8592.
[38]	Zhang Y, Liu XY, Ren SX. Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis[J]. Expert Opin Biol Ther, 2025, 25(5): 1-7. DOI: 10.1080/14712598.2025.2487512.
[39]	Li L, Li J, Tang H, et al. EP.12.38 Firmonertinib (160Mg) combined with chemotherapy as first-line treatment for advanced NSCLC patients with EGFR mutations and cns metastases[J]. J Thorac Oncol, 2025, 20(10): S812. DOI: 10.1016/j.jtho.2025.09.1568.
[40]	Liu Z, Shan D, Han X. Ivonescimab plus chemotherapy in patients with EGFR variant non-small cell lung cancer[J]. JAMA, 2025, 333(2): 172-173. DOI: 10.1001/jama.2024.23091. pmid: 39661345
[41]	Brazel D, Nagasaka M. Spotlight on amivantamab (JNJ-61186372) for EGFR exon 20 insertions positive non-small cell lung cancer[J]. Lung Cancer (Auckl), 2021, 12: 133-138. DOI: 10.2147/LCTT.S337861.
[42]	Zhou CC, Tang KJ, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions[J]. N Engl J Med, 2023, 389(22): 2039-2051. DOI: 10.1056/NEJMoa2306441.
[43]	Romero D. MARIPOSA demonstrates overall survival benefit from amivantamab-lazertinib[J]. Nat Rev Clin Oncol, 2025, 22(11): 801. DOI: 10.1038/s41571-025-01081-3.